Evidence map›Paper›PMID 40286167›Full record

ArticleMolecules (Basel, Switzerland)2025

Structure Determination of Tegoprazan((

Seah Ryu, JooHo Lee, Jason Kim, Tokutaro Yamaguchi

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Seah RyuJ2Hbiotech Inc. Corp, #210, B dong, 142-10, Saneop-ro 156beon-gil, Gwonseon-gu, Suwon-si 16648, Gyeonggi-do, Republic of Korea.
JooHo LeeJ2Hbiotech Inc. Corp, #210, B dong, 142-10, Saneop-ro 156beon-gil, Gwonseon-gu, Suwon-si 16648, Gyeonggi-do, Republic of Korea.
Jason KimJ2Hbiotech Inc. Corp, #210, B dong, 142-10, Saneop-ro 156beon-gil, Gwonseon-gu, Suwon-si 16648, Gyeonggi-do, Republic of Korea.
Tokutaro YamaguchiJ2Hbiotech Inc. Corp, #210, B dong, 142-10, Saneop-ro 156beon-gil, Gwonseon-gu, Suwon-si 16648, Gyeonggi-do, Republic of Korea.ORCID 0000-0002-5160-7174

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tegoprazan is a potassium ion-competitive acid blocker (P-CAB) and a novel inhibitor of gastric acid secretion. The compound exists in two crystalline polymorphs, A and B, whose structures had not previously been reported. In this study, both polymorphs were analyzed by liquid- and solid-state NMR, revealing identical tautomeric states. Using this information, the crystal structures were determined from laboratory powder X-ray diffraction data by simulated annealing and Rietveld refinement. Both forms were found to crystallize in the monoclinic space group P2

Indexed as

desmotropismDFT-Dpowder X-ray diffractionSDPDtautomerismTegoprazan

Identifiers

PMID40286167
PMCPMC11990383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.